Meir Azulay, MSc
Chief Executive Officer
Meir Azulay (MSc) is the CEO of BioXL, bringing several decades of experience in biopharmaceutical process development and manufacturing. He previously worked at Merck-Serono, where he played a key role in the development and manufacturing of Rebif, a blockbuster drug for multiple sclerosis. Meir holds an MSc in Biochemistry from the Hebrew University in Jerusalem. Since 2005, he has founded and managed a Contract Development and Manufacturing Organization (CDMO) and co-founded several startups in the biopharma, food-tech, and biotech sectors. His extensive background in the industry positions him as a leader in advancing innovative biopharmaceutical solutions.
Avraham Laban, PhD
Chief Technology Officer, Portfolio Manager
Dr. Avraham Laban (PhD), Chief Technology Officer (CTO) and Portfolio Manager at BioXL, brings extensive experience in drug development, enzyme production, and biochemical analysis to the team. He has held research and teaching positions at prestigious institutions such as MIT and Harvard, as well as in Israel. Dr. Laban has founded and managed a startup in the renewable energy sector and is a co-founder of several startups in biopharma, food-tech, and biotech. His diverse expertise positions him as a key leader in advancing innovative solutions within the biopharmaceutical landscape.
Dr. Ouri Fischel, PhD, MBA
Business Development Director
Dr. Ouri Fischel (PhD, MBA), Business Development Director at BioXL, specializes in drug discovery and development. He has extensive experience working on protein kinase inhibitors for cancer treatment in collaboration with Sanofi-Aventis and Janssen Pharmaceutica (Johnson & Johnson). With a PhD in Pharmacology and an MBA in Biomedical Management, Dr. Fischel combines scientific expertise with strong business acumen. He has successfully raised funding for companies focused on Rational Drug Design, Cheminformatics, and Machine Learning, positioning him as a key contributor to BioXL’s strategic initiatives and growth.
Stephen Simes, BSc, MBA
Chairman of the Board
Stephen Simes (BSc, MBA) is the Chairman of the BioXL board and a seasoned leader in the biopharmaceutical industry. With extensive experience as a CEO and board member, Stephen has a proven track record in the management, financing, and governance of public biopharma companies, overseeing numerous FDA-approved and R&D-stage products. Throughout his career, he has successfully raised over $500 million through various financing transactions, product licensing agreements, and mergers and acquisitions. His strategic insights and leadership have been instrumental in driving growth and innovation within the biopharmaceutical sector.
ToonLee Ng, BSc Hons, MBA
Asia Market Development
ToonLee Ng (BSc Hons, MBA) leads BioXL Asia and is responsible for market development within the company. She is passionate about addressing real-world challenges through innovative business models. ToonLee owns two companies: Venture Sense, which focuses on commercializing ventures across borders and is incubating a co-working model farm to enhance trade and investment between Singapore and the Philippines; and Shiox Films, which is dedicated to merging entertainment with social impact. She plans to produce a feature film centered on cancer and longevity. Her diverse experience and entrepreneurial spirit make her a vital asset to BioXL’s mission of advancing healthcare solutions.